Covered recipient · General Payments record
MAEN ABDELRAHIM
Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$142,288.15
119 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $92,063.96 | 29 |
| Consulting Fee | $19,770.00 | 4 |
| Honoraria | $15,660.00 | 2 |
| Travel and Lodging | $12,451.17 | 40 |
| Food and Beverage | $2,343.02 | 44 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $47,247.51 | 30 |
| Ipsen Biopharmaceuticals, Inc | $33,465.00 | 17 |
| Seagen Inc. | $18,957.85 | 19 |
| PFIZER INC. | $11,344.52 | 15 |
| ARRAY BIOPHARMA INC | $9,749.55 | 9 |
| JAZZ PHARMACEUTICALS INC. | $7,500.00 | 1 |
| Astellas Pharma US Inc | $4,653.57 | 5 |
| Genentech USA, Inc. | $3,304.99 | 5 |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,438.43 | 2 |
| Exelixis Inc. | $1,980.00 | 1 |
| Daiichi Sankyo Inc. | $1,370.00 | 1 |
| Eisai Inc. | $97.75 | 5 |
| Merck Sharp & Dohme LLC | $58.75 | 3 |
| TAIHO ONCOLOGY, INC. | $42.73 | 2 |
| Amgen Inc. | $36.05 | 2 |
| Sirtex Medical Inc | $22.76 | 1 |
| AbbVie Inc. | $18.69 | 1 |
Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MAEN ABDELRAHIM
NPI 1518227735 · CMS profile ID 1147037
Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology
HOUSTON, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1518227735?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MAEN ABDELRAHIM, NPI 1518227735, CMS profile ID 1147037. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1518227735?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MAEN ABDELRAHIM, NPI 1518227735, CMS profile ID 1147037. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1518227735?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MAEN ABDELRAHIM, NPI 1518227735, CMS profile ID 1147037, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 119 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1518227735?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
119 matching records · $142,288.15 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 119.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Ipsen Biopharmaceuticals, Inc | $212.94 | 08/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458651 | CMS |
| Ipsen Biopharmaceuticals, Inc | $382.81 | 08/24/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458657 | CMS |
| Ipsen Biopharmaceuticals, Inc | $6,960.00 | 08/24/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458663 | CMS |
| PFIZER INC. | $406.01 | 08/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049915283 | CMS |
| Eisai Inc. | $19.74 | 08/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023320575 | CMS |
| Astellas Pharma US Inc | $750.00 | 08/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034377847 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,750.00 | 07/31/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011663315 | CMS |
| Eisai Inc. | $24.57 | 07/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023320577 | CMS |
| Merck Sharp & Dohme LLC | $23.26 | 07/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048593109 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.38 | 06/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016000741 | CMS |
| AstraZeneca Pharmaceuticals LP | $116.29 | 06/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016146145 | CMS |
| Merck Sharp & Dohme LLC | $20.36 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1048593113 | CMS |
| Seagen Inc. | $40.55 | 06/16/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760383 | CMS |
| Seagen Inc. | $41.40 | 06/16/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760391 | CMS |
| Amgen Inc. | $20.42 | 06/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020006157 | CMS |
| Amgen Inc. | $15.63 | 05/31/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1020006155 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 05/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012006451 | CMS |
| Seagen Inc. | $8,050.00 | 05/12/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760377 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.98 | 05/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1011850719 | CMS |
| AstraZeneca Pharmaceuticals LP | $175.61 | 05/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012111109 | CMS |
| AstraZeneca Pharmaceuticals LP | $28.64 | 05/11/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014622387 | CMS |
| AstraZeneca Pharmaceuticals LP | $133.81 | 05/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015975711 | CMS |
| AstraZeneca Pharmaceuticals LP | $379.80 | 05/11/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016069193 | CMS |
| Eisai Inc. | $15.17 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023320573 | CMS |
| AstraZeneca Pharmaceuticals LP | $17.90 | 05/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015704397 | CMS |
| Seagen Inc. | $333.35 | 04/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760403 | CMS |
| Seagen Inc. | $40.00 | 04/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760411 | CMS |
| Seagen Inc. | $62.00 | 04/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760417 | CMS |
| Seagen Inc. | $185.00 | 04/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760429 | CMS |
| Seagen Inc. | $249.96 | 04/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760397 | CMS |
| Seagen Inc. | $185.00 | 04/28/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760425 | CMS |
| AstraZeneca Pharmaceuticals LP | $5,500.00 | 04/21/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016263379 | CMS |
| Ipsen Biopharmaceuticals, Inc | $45.00 | 04/20/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458603 | CMS |
| Ipsen Biopharmaceuticals, Inc | $8,700.00 | 04/20/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458629 | CMS |
| Ipsen Biopharmaceuticals, Inc | $83.87 | 04/20/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458635 | CMS |
| AstraZeneca Pharmaceuticals LP | $102.80 | 04/19/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1012097415 | CMS |
| AstraZeneca Pharmaceuticals LP | $187.96 | 04/19/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1014867321 | CMS |
| AstraZeneca Pharmaceuticals LP | $235.08 | 04/19/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1015698825 | CMS |
| AstraZeneca Pharmaceuticals LP | $80.51 | 04/19/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1016012901 | CMS |
| ARRAY BIOPHARMA INC | $236.38 | 04/12/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049412239 | CMS |
| Seagen Inc. | $350.00 | 04/07/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995760695 | CMS |
| ARRAY BIOPHARMA INC | $4,150.00 | 03/17/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049558047 | CMS |
| ARRAY BIOPHARMA INC | $253.41 | 03/04/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049164525 | CMS |
| ARRAY BIOPHARMA INC | $394.36 | 03/04/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049203803 | CMS |
| ARRAY BIOPHARMA INC | $423.72 | 03/04/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1049638431 | CMS |
| Eisai Inc. | $23.59 | 03/02/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1023320571 | CMS |
| TAIHO ONCOLOGY, INC. | $23.17 | 03/01/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1055228425 | CMS |
| Ipsen Biopharmaceuticals, Inc | $1,740.00 | 02/25/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1045458585 | CMS |
| Genentech USA, Inc. | $38.05 | 02/23/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040442581 | CMS |
| Genentech USA, Inc. | $2,850.00 | 02/23/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040442587 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $794,004.60 | 38 |
| PY2024 | Principal investigator | $380,887.91 | 70 |
| PY2023 | Principal investigator | $293,118.60 | 18 |
| PY2022 | Principal investigator | $454,080.68 | 11 |
| PY2021 | Principal investigator | $162,014.90 | 19 |
| PY2020 | Principal investigator | $128,202.23 | 19 |
| PY2019 | Recipient | $476.00 | 1 |
| PY2019 | Principal investigator | $35,009.69 | 43 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
38 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $79,527.39 | 12/19/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH | Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) plus oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients with Advanced Appendiceal Cancer | No dispute reported | 06/30/2026 | 1184285613 |
| Principal investigator 1 | Ipsen Biopharmaceuticals, Inc | $79,527.39 | 12/19/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH | Liposomal irinotecan (nal-IRI) plus 5- fluorouracil and leucovorin (5-FU/LV) plus oxaliplatin (NALIRIFOX) as First-Line Chemotherapy for Patients with Advanced Small Intestine and Appendiceal Cancers | No dispute reported | 06/30/2026 | 1184285615 |
| Principal investigator 1 | Genentech, Inc. | $46.40 | 12/11/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613449 |
| Principal investigator 1 | Genentech, Inc. | $1,950.00 | 11/20/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613444 |
| Principal investigator 1 | Genentech, Inc. | $7,920.15 | 10/16/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613439 |
| Principal investigator 1 | Astellas Pharma Global Development | $507.00 | 10/09/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186286 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $135,925.30 | 09/29/2025 | Non-covered Recipient Entity Methodist Hospital Research Institute | Maen Abdelrahim, MD - IIR-US-00326 - Houston Methodist Neal Cancer Center and Institute of Academic Medicine | No dispute reported | 06/30/2026 | 1225402189 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 09/18/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186284 |
| Principal investigator 1 | Genentech, Inc. | $3,120.00 | 09/02/2025 | Non-covered Recipient Entity Methodist Hospital Research Institute | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624689 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 09/02/2025 | Non-covered Recipient Entity Methodist Hospital Research Institute | A Phase II study of Atezolizumab with or without Bevacizumab in Patients with HCC | No dispute reported | 06/30/2026 | 1211624695 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $271,850.60 | 08/11/2025 | Non-covered Recipient Entity Methodist Hospital Research Institute | Maen Abdelrahim, MD - IIR-US-00326 - Houston Methodist Neal Cancer Center and Institute of Academic Medicine | No dispute reported | 06/30/2026 | 1225402191 |
| Principal investigator 1 | Genentech, Inc. | $7,920.15 | 07/10/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613436 |
| Principal investigator 1 | Genentech, Inc. | $9,870.15 | 07/02/2025 | Non-covered Recipient Entity METHODIST HOSPITAL RESEARCH INSTITUTE | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211624701 |
| Principal investigator 1 | Genentech, Inc. | $46.40 | 06/12/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613433 |
| Principal investigator 1 | Astellas Pharma Global Development | $3,120.00 | 04/17/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186282 |
| Principal investigator 1 | Genentech, Inc. | $8,407.65 | 04/17/2025 | Non-covered Recipient Entity HOUSTON METHODIST ACADEMIC INST | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211613428 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $29,754.10 | 04/17/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH | An Open-label, Randomised, Multicentre, Phase III Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Leucovorin Versus Nab-paclitaxel Plus Gemcitabine in Subjects Who Have Not Previously Received Chemotherapy for Metastatic Adenocarcinoma of the Pancreas | No dispute reported | 06/30/2026 | 1176544881 |
| Principal investigator 1 | Genentech, Inc. | $30,992.62 | 04/03/2025 | Covered Recipient Teaching Hospital The Methodist Hospital | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211557375 |
| Principal investigator 1 | Eisai Inc. | $1,820.00 | 03/17/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561417 |
| Principal investigator 1 | Eisai Inc. | $2,600.00 | 03/17/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561421 |
| Principal investigator 1 | Novocure Inc. | $6,500.00 | 03/13/2025 | Non-covered Recipient Entity The Methodist Hospital Research Ins | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856419 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,620.00 | 03/07/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186288 |
| Principal investigator 1 | Astellas Pharma Global Development | $1,620.00 | 03/07/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186290 |
| Principal investigator 1 | Genentech, Inc. | $7,920.15 | 02/26/2025 | Covered Recipient Teaching Hospital The Methodist Hospital | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211557369 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $1,700.00 | 02/21/2025 | Non-covered Recipient Entity Houston Methodist Hospital | A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab or Docetaxel in Participants with Advanced Solid Tumors | No dispute reported | 06/30/2026 | 1235996821 |
| Principal investigator 1 | Eisai Inc. | $17,068.73 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561413 |
| Principal investigator 1 | Eisai Inc. | $17,068.73 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561415 |
| Principal investigator 1 | Eisai Inc. | $1,300.00 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561419 |
| Principal investigator 1 | Eisai Inc. | $17,068.73 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561423 |
| Principal investigator 1 | Eisai Inc. | $17,068.73 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561425 |
| Principal investigator 1 | Eisai Inc. | $17,068.73 | 02/18/2025 | Non-covered Recipient Entity The Methodist Hospital Research Institute | Neoadjuvant Combination Therapy of Lenvima plus Transcatheter Arterial Chemoembolization (TACE) or Transarterial Radioembolization (TARE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma | No dispute reported | 06/30/2026 | 1244561427 |
| Principal investigator 1 | Exelixis Inc. | $975.00 | 02/14/2025 | Non-covered Recipient Entity Houston Methodist Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380884 |
| Principal investigator 1 | Exelixis Inc. | $1,300.00 | 02/14/2025 | Non-covered Recipient Entity Houston Methodist Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380886 |
| Principal investigator 1 | Exelixis Inc. | $1,326.00 | 02/14/2025 | Non-covered Recipient Entity Houston Methodist Research Institute | A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors | No dispute reported | 06/30/2026 | 1222380888 |
| Principal investigator 1 | Novocure Inc. | $2,500.00 | 02/13/2025 | Non-covered Recipient Entity The Methodist Hospital Research Ins | EF-27 Pivotal, randomized, open-label study of Tumor Treating Fields (TTFields, 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma | No dispute reported | 06/30/2026 | 1250856683 |
| Principal investigator 1 | Astellas Pharma Global Development | $500.00 | 01/23/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186280 |
| Principal investigator 1 | Genentech, Inc. | $487.50 | 01/17/2025 | Covered Recipient Teaching Hospital The Methodist Hospital | Bridging HCC to LT | No dispute reported | 06/30/2026 | 1211557373 |
| Principal investigator 1 | Astellas Pharma Global Development | $507.00 | 01/09/2025 | Non-covered Recipient Entity THE METHODIST HOSPITAL RESEARCH INSTITUTE | A Phase 2, Open-Label, Randomized Study to Assess the Antitumor Activity and Safety of Zolbetuximab (IMAB362) in Combination With Nab-Paclitaxel and Gemcitabine as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma | No dispute reported | 06/30/2026 | 1234186278 |